Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 nov. 2021 08h15 HE | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
09 juil. 2020 07h00 HE | Source: Mateon Therapeutics, Inc.

Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19

- Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN). Agoura Hills, California, July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a late-stage...
07 juil. 2020 06h41 HE | Source: Mateon Therapeutics, Inc.

Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine

Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB:...